These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36622889)

  • 41. Two Randomized, Double-Blind, Split-Face Studies to Compare the Irritation Potential of Two Topical Acne Fixed Combinations Over a 21-Day Treatment Period.
    Bhatia N; Bhatt V; Martin G; Pillai R
    J Drugs Dermatol; 2016 Jun; 15(6):721-6. PubMed ID: 27272079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference.
    Dunlap FE; Mills OH; Tuley MR; Baker MD; Plott RT
    Br J Dermatol; 1998 Oct; 139 Suppl 52():17-22. PubMed ID: 9990416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Facial tolerability of topical retinoid therapy.
    Leyden J; Grove G; Zerweck C
    J Drugs Dermatol; 2004; 3(6):641-51. PubMed ID: 15624747
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 50 Years of Topical Retinoids for Acne: Evolution of Treatment.
    Baldwin H; Webster G; Stein Gold L; Callender V; Cook-Bolden FE; Guenin E
    Am J Clin Dermatol; 2021 May; 22(3):315-327. PubMed ID: 33871811
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tazarotene 0.045% Lotion: A Novel Retinoid Formulation.
    Mohney LA; Singh R; Feldman SR
    Ann Pharmacother; 2022 Oct; 56(10):1174-1180. PubMed ID: 35112585
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical evidence for the role of a topical anti-inflammatory agent in comedonal acne: findings from a randomized study of dapsone gel 5% in combination with tazarotene cream 0.1% in patients with acne vulgaris.
    Tanghetti E; Dhawan S; Green L; Ling M; Downie J; Germain MA; Kasteler JS; Kircik L; Oefelein MG; Draelos Z
    J Drugs Dermatol; 2011 Jul; 10(7):783-92. PubMed ID: 21720661
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne Patients: Pooled Phase 3 Analysis by Age and Sex.
    Green LJ; Del Rosso JQ; Tanghetti EA; Guenin E
    J Drugs Dermatol; 2021 Jun; 20(6):608-615. PubMed ID: 34076400
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative tolerance of adapalene 0.1% gel and six different tretinoin formulations.
    Galvin SA; Gilbert R; Baker M; Guibal F; Tuley MR
    Br J Dermatol; 1998 Oct; 139 Suppl 52():34-40. PubMed ID: 9990419
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Topical adapalene gel 0.1% vs. isotretinoin gel 0.05% in the treatment of acne vulgaris: a randomized open-label clinical trial.
    Ioannides D; Rigopoulos D; Katsambas A
    Br J Dermatol; 2002 Sep; 147(3):523-7. PubMed ID: 12207595
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and tolerance of adapalene cream 0.1% compared with its cream vehicle for the treatment of acne vulgaris.
    Lucky A; Jorizzo JL; Rodriguez D; Jones TM; Stewart DM; Tschen EH; Kanof NB; Miller BH; Wilson DC; Loven KH
    Cutis; 2001 Oct; 68(4 Suppl):34-40. PubMed ID: 11845946
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adapalene 0.1% gel has low skin-irritation potential.
    Verschoore M; Poncet M; Czernielewski J; Sorba V; Clucas A
    J Am Acad Dermatol; 1997 Jun; 36(6 Pt 2):S104-9. PubMed ID: 9204086
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial.
    Tanghetti E; Abramovits W; Solomon B; Loven K; Shalita A
    J Drugs Dermatol; 2006 Mar; 5(3):256-61. PubMed ID: 16573259
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Race/Ethnicity.
    Bhatia N; Weiss JS; Sadick N; Cook-Bolden FE; Tyring SK; Guenin E; Loncaric A; Harris S
    J Drugs Dermatol; 2020 Jul; 19(7):727-734. PubMed ID: 32726105
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream.
    Draelos Z; Tanghetti E; Guenin E
    J Drugs Dermatol; 2022 Aug; 21(8):875-880. PubMed ID: 35946981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris.
    Kircik L
    J Drugs Dermatol; 2022 Jul; 21(7):713-716. PubMed ID: 35816073
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adapalene-benzoyl peroxide once-daily, fixed-dose combination gel for the treatment of acne vulgaris: a randomized, bilateral (split-face), dose-assessment study of cutaneous tolerability in healthy participants.
    Andres P; Pernin C; Poncet M
    Cutis; 2008 Mar; 81(3):278-84. PubMed ID: 18441854
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A comparison of adapalene gel 0.1% vs. tretinoin gel 0.025% in the treatment of acne vulgaris in China.
    Tu P; Li GQ; Zhu XJ; Zheng J; Wong WZ
    J Eur Acad Dermatol Venereol; 2001; 15 Suppl 3():31-6. PubMed ID: 11843231
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne.
    Tan J; Thiboutot D; Popp G; Gooderham M; Lynde C; Del Rosso J; Weiss J; Blume-Peytavi U; Weglovska J; Johnson S; Parish L; Witkowska D; Sanchez Colon N; Alió Saenz A; Ahmad F; Graeber M; Stein Gold L
    J Am Acad Dermatol; 2019 Jun; 80(6):1691-1699. PubMed ID: 30802558
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Topical Retinoids in Acne Vulgaris: A Systematic Review.
    Kolli SS; Pecone D; Pona A; Cline A; Feldman SR
    Am J Clin Dermatol; 2019 Jun; 20(3):345-365. PubMed ID: 30674002
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tazarotene 0.045% Lotion for Moderate-to-Severe Acne in Male and Female Participants: A Phase II
    Baldwin HE; Green LJ; Kircik L; Guenin EP; Forest AL; Pillai R
    J Clin Aesthet Dermatol; 2021 Apr; 14(4):E53-E60. PubMed ID: 34055190
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.